TABLE 4. Randomized Controlled Trials for Treatment of Cancer-Related Venous Thromboembolism (VTE).

From Falanga A, Lee AY, Streiff MB, Lyman GH. 2008 ASCO Education Book: 258-268.⁴⁵ Adapted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.

Study	No. of patients	Treatment regimens	Proportion of patients experiencing event during treatment period (%)			Statistical inference
			Recurrent VTE	Major bleeding	Death
Lee et al. 200346	336	Dalteparin (200 IU/kg OD) for 5-7 days + warfarin (target INR 2-3) for 6 months	16	4	41	P = .002 for recurrent VTE; NS for major bleeding and for death
	336	Dalteparin (200 IU/kg OD) for 1 month + dalteparin (~150 IU/kg OD) for 5 months	8	6	39
Hull et al. 200647	100	IV UFH (APTT adjusted) for 6 days + warfarin (target INR 2-3) for 3 months	10	7*	19	NS
	100	Tinzaparin (175 IU/kg OD) for 3 months	6	7*	20
Meyer et al. 200248	71	Enoxaparin (1.5 mg/kg OD) for ≥ 4 days + warfarin (target INR2-3) for 3 months	21.1 †	16	22.7	NS
	67	Enoxaparin (1.5 mg/kg OD) for 3 months	10.5 †	7	11.3
Deitcher et al. 200649	30	Enoxaparin (1 mg/kg BID) for ≥ 5 days + warfarin (target INR2-3) for 178 days	10.0	2.9	32.4	ND for recurrent VTE or death; NS for major bleeding
	29	Enoxaparin (1 mg/kg BID) for 5 days + enoxaparin (1 mg/kg OD) for 175 days	6.9	6.5	22.6
	32	Enoxaparin (1 mg/kg BID) for 5 days + enoxaparin (1.5 mg/kg OD) for 175 days	6.3	11.1	41.7

^*Major bleeding rate does not include fatal bleeding.

^†Rate of recurrent VTE or major hemorrhage.

APTT, activated partial thromboplastin time; BID, twice-daily; INR, international normalized ratio; IV, intravenous; OD, once-daily; ND, not determined; NS, not significant; UFH, unfractionated heparin.